Better After CHoosing. Randomly Allocated or Patient Preference Based Treatment With Filgotinib or TNFi in RA (BACH)
Status:
Recruiting
Trial end date:
2023-04-01
Target enrollment:
Participant gender:
Summary
Despite their efficacy in the treatment of Rheumatoid Arthritis and their partial advantage
over traditional bDMARDs ( biological Disease Modifying antirheumatic drugs), JAK inhibitors
(JAKi or tsDMARDs) have not gained preference over Tumor Necrosis Factor inhibitors (TNFi) in
guidelines or clinical practice. The biggest influence on recent guidelines has been the
"Treat To Target" principle (T2T), in which Shared Decision Making (SDM) plays a key part.
Patient preference has proven to be a large barrier in treatment adjustments (14- 37%) while
patients showed better adherence and higher treatment satisfaction when engaged in Shared
Decision Making. From survey studies it is suggested that patient preference and satisfaction
will be in favour of oral JAK inhibitors over parenteral biologics.The investigators want to
establish the treatment preference of patients with active RA and compare the treatment
satisfaction of patients who are given the opportunity to choose between the JAKi filgotinib
and TNFi, to the treatment satisfaction of patients who are randomized to the same treatment
options.
In addition to higher treatment satisfaction and better adherence, the investigators expect
to find an improvement in DAS28-, HAQ-, SQUASH- and WPAI-scores and also an improved activity
and work productivity.
Phase:
Phase 4
Details
Lead Sponsor:
R.Bos
Collaborators:
Galapagos NV Leiden University Medical Center Medical Centre Leeuwarden